Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improve survival in ES-SCLC compared with chemotherapy alone. No significant difference in overall survival or progression-free ...

Novel therapies targeting molecular pathways, including DLL3 and PARP inhibitors, show promise in improving SCLC survival outcomes. Tarlatamab, a DLL3-targeting bispecific T-cell engager, achieved a ...

T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...

There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small cell lung cancer is often categorized in one of two stages: limited or ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...